Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non-Current Deffered Revenue (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $8.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 24.3% to $8.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.7 million, a 24.3% decrease, with the full-year FY2024 number at $11.0 million, down 26.36% from a year prior.
  • Non-Current Deffered Revenue was $8.7 million for Q3 2025 at Orchestra BioMed Holdings, down from $9.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $14.9 million in Q4 2023 to a low of $5.6 million in Q3 2022.
  • A 4-year average of $11.7 million and a median of $12.7 million in 2024 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 147.23% in 2023, then dropped 26.36% in 2024.
  • Orchestra BioMed Holdings' Non-Current Deffered Revenue stood at $13.1 million in 2022, then rose by 13.89% to $14.9 million in 2023, then fell by 26.36% to $11.0 million in 2024, then decreased by 21.2% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Non-Current Deffered Revenue are $8.7 million (Q3 2025), $9.6 million (Q2 2025), and $10.8 million (Q1 2025).